Lonza

Lonza is a Switzerland-based biotechnology company that develops and commercializes small molecule, specialty ingredients and related products for the pharmaceutical industry. Read more

Pierre-Alain Ruffieux's photo - CEO of Lonza

CEO

Pierre-Alain Ruffieux

CEO Approval Rating

96/100

Founded:

1897

Status:

PublicIndependent CompanySIX Swiss ExchangeLONN

LONZA TOP COMPETITORS OR ALTERNATIVES

RANK

COMPANY

CEO

CEO RATING

EMPLOYEES

FUNDING

REVENUE

Missing a competitor? Contribute!

Patheon has been one of Lonza's top competitors. Patheon is a Private company that was founded in 1974 in Durham, North Carolina. Patheon operates in the Pharmaceuticals industry. Compared to Lonza, Patheon has 4,756 fewer employees.

Kemin is seen as one of Lonza's biggest rivals. Kemin is a Private company that was founded in Des Moines, Iowa in 1961. Kemin is in the Food Processing industry. Kemin has 11,056 fewer employees vs. Lonza.

DSM is perceived as one of Lonza's biggest rivals. DSM was founded in Heerlen, Limburg} in 1902. Like Lonza, DSM also competes in the Biotechnology sector. Compared to Lonza, DSM generates $4.9B more revenue.

Weigh-in!

Help the Owler community know more

Competitor - 1/1

Is Barentz a competitor of Lonza?

Lonza Quarterly and Annual Revenue

Trailing 12-Months Trend (TTM)

Annual Revenue

$5.1B

Lonza's revenue is the ranked 4th among it's top 10 competitors. The top 10 competitors average 3.4B. Over the last three quarters, Lonza's revenue has decreased by 70.2%. Specifically, in Q4 2020's revenue was $483.8M; in Q3 2020, it was $483.8M; in Q2 2020, it was $1.6B.

Lonza Acquisitions

COMPANY ACQUIRED
ACQUISITION DATE
AMOUNT
DESCRIPTION
Octane Medical Group

Oct 2018

Source »
undisclosed
Octane develops regenerative medical solutions for cell therapy and medical device companies.
Micro-macinazione SA

Jul 2017

Source »
undisclosed
Micro-Macinazione is a provider of micronization services and equipment for pharmaceutical and chemical industries.
PharmaCell B.V.

May 2017

Source »
undisclosed
PharmaCell is a Contract Manufacturing Organization for developing cellular therapies and regenerative medicine.
Capsugel S.A.

Dec 2016

Source »
$5.5B
Capsugel designs, develops and manufactures dosage forms for biopharmaceutical, nutrition and health care industries.
InterHealth Nutraceuticals, Inc.

Aug 2016

Source »
$300M
InterHealth develops, manufactures, markets and distributes nutritional ingredients to the manufacturers of dietary supplements and cosmetic products.

These are all the companies that Lonza has acquired. Lonza has acquired 10 companies and its latest acquisition was Octane Medical Group in Oct 2018. Octane develops regenerative medical solutions for cell therapy and medical device companies.

Lonza Funding History

Since Lonza was founded in 1897, it has participated in 1 round of funding. In total Lonza has raised $874.0M. Lonza's funding round was on Jan 2017 for a total of $874.0M

ROUND

FUNDING DATE

AMOUNT

INVESTORS

Equity
Jan 2017
$874M
-

Since Lonza was founded in 1897, it has participated in 1 round of funding. In total Lonza has raised $874.0M. Lonza's funding round was on Jan 2017 for a total of $874.0M

Lonza Investments

COMPANY

DESCRIPTION

AMOUNT

INVESTMENT DATE

ROUND

EXIT DATE

Affinia Therapeutics is a Massachusetts-based pharmaceutical company that researches and develops gene therapies for the treatment of CNS and muscle disorders.
$110M
May 02, 2021
Series B
-
Dynamk Capital is an investment management firm that focuses on life science companies to accelerate their growth and technology adoption.
$65M
Apr 27, 2021
Investment Fund
-
Affinia Therapeutics is a Massachusetts-based pharmaceutical company that researches and develops gene therapies for the treatment of CNS and muscle disorders.
$60M
Mar 30, 2020
Series A
-

These are all the companies that Lonza has invested in. Lonza has invested 10 companies and its latest investment was Octane Medical Group in Oct 2018. Octane develops regenerative medical solutions for cell therapy and medical device companies.

Lonza News

June 7, 2021Manufacturing Chemist

Lonza and Moderna announce further manufacturing collaboration

In May 2020, the companies announced a ten-year strategic collaboration agreement to enable the manuf... See more »
June 2, 2021PharmaLive

Moderna plans mix of Covid-19 vaccine doses with new Lonza deal

Moderna is gearing up to halve the dose of the company's Covid-19 vaccine, the U.S. drugmaker said on... See more »
May 19, 2021Manufacturing Chemist

Lonza launches updated 4D-Nucleofector platform

The latest version of the technology maintains the same level of performance but enhances ease-of-use... See more »
May 13, 2021The Business Desk

Milestone reached for Alderley Park biotech firm | TheBusinessDesk.com

Infex Therapeutics is developing a novel therapy which targets serious recurrent respiratory infectio... See more »
May 7, 2021MarketScreener

Price Change Notification on Selected Product Portfolios

(marketscreener.com) Basel, Switzerland, 07 May, 2021 - Effective 10 May, 2021 or as dictated by the ... See more »
May 6, 2021The Pharma Letter

Lonza expands manufacturing in Visp (Switz) and Portsmouth (USA)

Swiss contract development and manufacturing organization (CDMO) Lonza today announced it will invest... See more »
May 6, 2021Outsourcing-Pharma

Lonza leader outlines small-molecule trends for 2021 and beyond

The head of small-molecule business for the pharma solutions specialist talks about obstacles, and ho... See more »

Lonza Press Releases

March 24, 2020Business Wire

TriumviraImmunologicsandLonzaAnnounceCollaborationtoDevelopInnovativePoint-of-CareManufacturingforTACT-CellTherapeuticTargetingSolidTumors

AUSTIN, Texas; HAMILTON, Ontario & BASEL, Switzerland--(BUSINESS WIRE)--Triumvira Immunologics, Inc. ... See more »
September 25, 2019PR Newswire

Lonza Commissioned World-Renowned Photographer, Bob Wolfenson, To Create 'Move To The Extra[Ordinary] ' Photography Exhibit To Promote Joint Health

NEW YORK, Sept. 25, 2019 /PRNewswire/ -- The 'Move To The Extra[Ordinary] ' art exhibit, curated and ... See more »
April 5, 2019EIN Presswire

Interview with Lonza AG

Interview with Ester Lovsin Barle from Lonza AG who is speaking at SMi's 3rd Annual Highly Potent Act... See more »
May 8, 2018econotimes

Proteon Therapeutics and Lonza Extend Manufacturing Agreement for Commercial Supply

BASEL, Switzerland and WALTHAM, Mass., May 08, 2018 -- Proteon Therapeutics, Inc. (Nasdaq:PRTO), a co... See more »
March 26, 2018GlobeNewswire

Organovo Division Samsara Sciences Announces Multi-Year Supply Agreement With Lonza Bioscience Solutions

SAN DIEGO, March 26, 2018 (GLOBE NEWSWIRE) -- Organovo Holdings, Inc. (NASDAQ:ONVO) ("Organovo") toda... See more »
March 19, 2018Industry Today

Key Players - BASF SE, Yara International, Lonza, DSM, Tata Chemicals

Animal Nutrition Chemicals -Market Demand, Growth, Opportunities and Analysis Of Top Key Player Forec... See more »
December 28, 2017Business Wire

Rapid Growth in Pharma Industry Key to Growth - Research and Markets

DUBLIN--(BUSINESS WIRE)--The "Cell Line Development Market: By Product, By Source, By Type, By Applic... See more »

Lonza Videos

Social Media

Lonza Headquarters

Muenchensteinerstrasse 38

Basel, Basel-City4002

41-61-316-81-11

Driving Directions »

Trending Companies

Lonza Summary

ABOUT

Overview

Lonza is a Switzerland-based biotechnology company that develops and commercializes small molecule, specialty ingredients and related products for the pharmaceutical industry. Lonza was founded in 1897. Lonza's headquarters is located in Basel, Basel-...

CEO

Lonza's CEO, Pierre-Alain Ruffieux, currently has an approval rating of 96%. Lonza's primary competitors are Patheon, Kemin & DSM.

Website

lonza.com

Frequently Asked Questions about Lonza

  1. When was Lonza founded?

    Lonza was founded in 1897
  2. Who is Lonza's CEO?

    Lonza's CEO is Pierre-Alain Ruffieux
  3. How much revenue does Lonza generate?

    Lonza generates $5.1B in revenue
  4. How much funding does Lonza have?

    Lonza has historically raised $874M in funding
  5. Where is Lonza's headquarters?

    Lonza's headquarters is in Basel Basel-City, CH
  1. How many employees does Lonza have?

    Lonza has 13,856 employees
  2. What sector does Lonza operate in?

    Lonza is in Biotechnology
  3. Who are Lonza's competitors?

    Lonza's top competitors are Patheon, Kemin, DSM
  4. Who has Lonza invested in?

    Lonza's has invested in companies such as Affinia Therapeutics, Dynamk Capital LLC, Affinia Therapeutics